Skip to main content

Peer Review reports

From: ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

Original Submission
26 Oct 2007 Submitted Original manuscript
19 Nov 2007 Reviewed Reviewer Report - Nathalie Théret
8 Dec 2007 Reviewed Reviewer Report - Christoph Röcken
31 Jan 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 2
31 Jan 2008 Submitted Manuscript version 2
26 Feb 2008 Reviewed Reviewer Report - Nathalie Théret
29 Feb 2008 Reviewed Reviewer Report - Xuemei Wang
5 Mar 2008 Reviewed Reviewer Report - Christoph Röcken
20 Mar 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 3
20 Mar 2008 Submitted Manuscript version 3
17 Apr 2008 Reviewed Reviewer Report - Xuemei Wang
22 Apr 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 4
22 Apr 2008 Submitted Manuscript version 4
16 Jun 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 5
16 Jun 2008 Submitted Manuscript version 5
18 Jun 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 6
18 Jun 2008 Submitted Manuscript version 6
Resubmission - Version 7
Submitted Manuscript version 7
Resubmission - Version 8
Submitted Manuscript version 8
Resubmission - Version 9
Submitted Manuscript version 9
Resubmission - Version 10
Submitted Manuscript version 10
24 Jun 2008 Author responded Author comments - Florian Fritzsche
Resubmission - Version 11
24 Jun 2008 Submitted Manuscript version 11
Publishing
26 Jun 2008 Editorially accepted
26 Jun 2008 Article published 10.1186/1471-2407-8-179

You can find further information about peer review here.

Back to article page